Page last updated: 2024-11-10

Nb-Palmitoyltryptamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID3726592
CHEMBL ID491543
CHEBI ID180747
SCHEMBL ID1725724

Synonyms (22)

Synonym
21469-15-8
nb-palmitoyltryptamine
CHEBI:180747
MLS001049060
smr000386898
n-[2-(1h-indol-3-yl)ethyl]hexadecanamide
n-palmitoyltryptamine
CHEMBL491543
HMS2271B05
palmitoyl tryptamine
1l1x9fsi7p ,
unii-1l1x9fsi7p
hexadecanamide, n-(2-(1h-indol-3-yl)ethyl)-
palmitoyl tryptamine [inci]
SCHEMBL1725724
DTXSID60175748
AKOS030489067
hexadecanoic acid tryptamide, standard for gc
nb-hexadecanoyltryptamine
STL564472
Q27252556
hexadecanoic acid tryptamide
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
indolesAny compound containing an indole skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
USP1 protein, partialHomo sapiens (human)Potency5.62340.031637.5844354.8130AID743255
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency1.00000.707936.904389.1251AID504333
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency89.12510.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency23.10930.004611.374133.4983AID624296
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (27)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID380852Cytotoxicity against human PaCa2 cells1999Journal of natural products, Aug, Volume: 62, Issue:8
Tryptamine derived amides and acetogenins from the seeds of Rollinia mucosa.
AID492254Antioxidant activity in mesecephalic neuron assessed as ROS production at 10 nM by dihydrorhodamine-123 incorporation assay relative to control2010Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
Tryptamine-derived alkaloids from Annonaceae exerting neurotrophin-like properties on primary dopaminergic neurons.
AID380851Cytotoxicity against human PC-3 cells1999Journal of natural products, Aug, Volume: 62, Issue:8
Tryptamine derived amides and acetogenins from the seeds of Rollinia mucosa.
AID380847Cytotoxicity against human A549 cells1999Journal of natural products, Aug, Volume: 62, Issue:8
Tryptamine derived amides and acetogenins from the seeds of Rollinia mucosa.
AID380846Toxicity in Artemia salina1999Journal of natural products, Aug, Volume: 62, Issue:8
Tryptamine derived amides and acetogenins from the seeds of Rollinia mucosa.
AID492251Neuritogenic effect in rat DA neurons assessed as total neurite length per tyrosine hydrolase immunopositive neurons at 10 nM relative to control2010Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
Tryptamine-derived alkaloids from Annonaceae exerting neurotrophin-like properties on primary dopaminergic neurons.
AID492249Neuroprotective activity against degeneration of rat DA neurons assessed as tyrosine hydrolase immunopositive neurons at 10 nM by immunofluorescence staining relative to control2010Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
Tryptamine-derived alkaloids from Annonaceae exerting neurotrophin-like properties on primary dopaminergic neurons.
AID380850Cytotoxicity against human A298 cells1999Journal of natural products, Aug, Volume: 62, Issue:8
Tryptamine derived amides and acetogenins from the seeds of Rollinia mucosa.
AID492253Antioxidant activity assessed as ABTS radical scavenging activity2010Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
Tryptamine-derived alkaloids from Annonaceae exerting neurotrophin-like properties on primary dopaminergic neurons.
AID380848Cytotoxicity against human MCF7 cells1999Journal of natural products, Aug, Volume: 62, Issue:8
Tryptamine derived amides and acetogenins from the seeds of Rollinia mucosa.
AID380849Cytotoxicity against human HT-29 cells1999Journal of natural products, Aug, Volume: 62, Issue:8
Tryptamine derived amides and acetogenins from the seeds of Rollinia mucosa.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (12.50)18.2507
2000's1 (12.50)29.6817
2010's4 (50.00)24.3611
2020's2 (25.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.70

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.70 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.90 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.70)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]